Package Leaflet: Information for the User
Meropenem Hikma 2 g Powder for Solution for Injection and Infusion
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the Package Leaflet
Meropenem Hikma contains the active substance meropenem, which belongs to a group of medicines called carbapenem antibiotics.
It works by killing bacteria that can cause serious infections.
Antibiotics are used to treat bacterial infections and do not work for viral infections such as flu or the common cold.
It is important that you follow the instructions regarding dose, administration interval, and treatment duration indicated by your doctor.
Do not store or reuse this medicine. If you have any leftover antibiotic after finishing treatment, return it to the pharmacy for proper disposal. Do not throw medicines down the drain or in the trash.
Meropenem is used to treat the following in adults and children from 3 months of age:
Meropenem may be used to treat patients with low levels of white blood cells (neutropenia) who have fever that is suspected to be due to a bacterial infection.
Meropenem can be used to treat bacterial infection of the blood that may be associated with one of the aforementioned infections.
Do not useMeropenem Hikma:
Warnings and precautions
Consult your doctor or nurse before starting to use Meropenem Hikma:
You may develop a positive reaction to a test (Coombs test) that indicates the presence of antibodies that can destroy red blood cells. Your doctor will discuss this with you.
Liver problems
Tell your doctor if you notice yellowing of the skin and eyes, itching of the skin, dark-colored urine, or light-colored stools. This may be a sign of liver problems that your doctor should check.
You may develop signs and symptoms of severe skin reactions (see section 4). If this happens, consult your doctor or nurse immediately so that they can treat the symptoms.
If you are in any of these situations, or if you have doubts, consult your doctor or nurse before using Meropenem Hikma.
Other medicines and Meropenem Hikma
Tell your doctor or nurse if you are using, have recently used, or might use any other medicines.
Meropenem may affect the way some medicines work, and some of these may have an effect on meropenem.
In particular, tell your doctor or nurse if you are taking any of the following medicines:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
It is preferable to avoid the use of meropenem during pregnancy. Your doctor will decide if you should use Meropenem.
It is very important that you inform your doctor if you are breastfeeding or plan to breastfeed, before receiving treatment with meropenem. A small amount of this medicine may pass into breast milk. Therefore, your doctor will decide if you should use Meropenem Hikma during breastfeeding.
Driving and using machines
No studies have been performed on the effects on the ability to drive and use machines.
However, meropenem has been associated with headache and tingling or numbness in the skin (paresthesia); and involuntary muscle movements, which can cause the body to shake rapidly and uncontrollably (convulsions), usually accompanied by loss of consciousness, and this may affect your ability to drive or use machines.
Do not drive or use machines if you experience this side effect.
Meropenem Hikma contains sodium
This medicine contains 180 mg of sodium (main component of table/cooking salt) per 2 g dose. This is equivalent to 9% of the maximum daily intake of sodium recommended for an adult.
If you have a condition that requires you to control your sodium intake, inform your doctor or nurse.
Follow exactly the administration instructions of this medicine indicated by your doctor or nurse. If in doubt, consult your doctor or nurse again.
Use in adults
Use in children and adolescents
How to use Meropenem Hikma
However, some patients, parents, or caregivers are trained to administer Meropenem Hikma at home. The instructions for this are found in this leaflet (in the section called “Instructions for administering Meropenem Hikma to yourself or another person at home”). Follow exactly the administration instructions of Meropenem Hikma indicated by your doctor. Consult your doctor if you have doubts.
If you use more Meropenem Hikma than you should
If you accidentally use more than the prescribed dose, contact your doctor, go to the nearest hospital immediately, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount received.
If you forget to use Meropenem Hikma
If you forget an injection, you should receive it as soon as possible. However, if it is almost time to administer the next injection, do not receive the forgotten one.
Do not use a double dose (two injections at the same time) to make up for forgotten doses.
If you stop treatment with Meropenem Hikma
Do not stop Meropenem Hikma until your doctor tells you to.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Severe allergic reactions
If you experience a severe allergic reaction , stop taking Meropenem Hikma and go to the doctor immediately.You may need urgent medical treatment. The signs and symptoms can include a sudden onset of:
Damage to red blood cells (frequency not known)
The symptoms include:
If you notice any of the above, go to the doctor immediately.
Other possible side effects:
Frequent (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
Do not store above 30°C.
Injection
After reconstitution: The reconstituted injectable solutions for intravenous use should be used immediately. The time between the start of reconstitution and the end of intravenous injection should not exceed:
There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.
After reconstitution, the solution should be colorless to pale yellow.
Infusion
After reconstitution: The reconstituted solutions for intravenous infusion should be used immediately. The time between the start of reconstitution and the end of intravenous infusion should not exceed:
From a microbiological point of view, unless the method of opening/reconstitution/dilution eliminates the risk of microbiological contamination, the product should be used immediately.
If not used immediately, the storage times and conditions are the responsibility of the user.
Do not freeze the reconstituted solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition ofMeropenem Hikma
Each vial contains meropenem trihydrate equivalent to 2 g of anhydrous meropenem.
The other component is anhydrous sodium carbonate.
Appearance of the Product and Container Contents
Meropenem Hikma is a white to light yellow powder, for solution for injection or infusion in a glass vial with a rubber stopper and an aluminum flip-off cap.
Container sizes of 1, 6, or 10 vials.
Not all container sizes may be marketed.
Marketing Authorization Holder
Hikma Farmacêutica (Portugal) S.A.
Estrada do Rio da Mó, nº8, 8A e 8B, Fervença
2705-906 Terrugem SNT
Portugal
Manufacturer
ACS Dobfar S.p.A Nucleo Industriale S. Atto
64100 TERAMO
Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Hikma España, S.L.U.
Calle Anabel Segura nº11, Edificio A, planta 1ª, oficina 2
28108 - Alcobendas, Madrid
Spain
This medication is authorized in the Member States of the European Economic Area under the following names:
Austria: Meropenem Hikma 2g Pulver zur Herstellung einer Injektions-/Infusionslösung
Ireland: Meropenem 2g Powder for solution for injection/infusion
Italy: Meropenem Hikma 2g Polvere per soluzione iniettabile o infusione
Germany: Meropenem Hikma 2g Pulver zur Herstellung einer Injektions-/Infusionslösung
Portugal: Meropenem Hikma 2g Pó para solução injetável ou para perfusão
Netherlands: Meropenem Hikma 2g Poeder voor oplossing injectie voor infusie
Spain: Meropenem Hikma 2 g polvo para solución inyectable y para perfusión
United Kingdom: Meropenem 2g Powder for solution for injection/infusion
France: Meropenem Hikma 2g Poudre pour solution injectable/pour perfusion
Date of the last revision of thisleaflet: August 2025.
Other sources of information:
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
Health Advice/Education Antibiotics are used to treat infections caused by bacteria. They have no effect against infections caused by viruses. Sometimes a bacterial infection does not respond to treatment with an antibiotic. One of the most common reasons for this to happen is that the bacteria causing the infection are resistant to the antibiotic being taken. This means they can survive and even multiply, despite the antibiotic. Bacteria can become resistant to antibiotics for many reasons. Using antibiotics with caution can help reduce the opportunity for bacteria to become resistant to them. When your doctor prescribes antibiotic treatment, it is to treat only your current illness. Paying attention to the following advice will help prevent the appearance of resistant bacteria that could stop the antibiotic from working.
|
This information is intended only for healthcare professionals:
The following sections contain practical information about the preparation and administration of the product. When the prescriber assesses the suitability for use in a particular patient, they should be familiar with the medication's technical data sheet. See also section 3 "How to use Meropenem" in this leaflet.
Instructions for administering Meropenem Hikma to yourself or another person at home
Some patients, parents, and caregivers are trained to administer Meropenem Hikma at home.
Warning – You should only administer this medication to yourself or another person at home after a doctor or nurse has trained you.
Dose of Meropenem Hikma | Amount of "Water for injections" needed for dilution |
500 mg (milligrams) | 10 ml (milliliters) |
1 g (gram) | 20 ml |
1.5 g | 30 ml |
2 g | 40 ml |
Note that:If the amount of Meropenem Hikma prescribed for you is more than 1 g, you will need to use more than one Meropenem Hikma vial. You can then draw up the liquid from the vials into a syringe.
Administration of the injectable
You can administer this medication through a peripheral intravenous catheter, or through a port or central line.
Administration ofMeropenem Hikmathrough a peripheral intravenous catheter
Administration ofMeropenem Hikmathrough a port or central line
Administration of Meropenem Hikma through intravenous infusion
Meropenem can be administered by intravenous infusion over approximately 15-30 minutes. For intravenous infusion, the Meropenem Hikma vials can be reconstituted directly to a final concentration of 1 to 20 mg/ml with 0.9% sodium chloride or 5% glucose solution for infusion.
The solution should be shaken before use
The vials are for single use.